StoxAurobindo Pharma vs Lupin: share price & financials comparison
NSE: AUROPHARMA vs LUPIN · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Aurobindo Pharma vs Lupin at a glance
Aurobindo Pharma (AUROPHARMA) has a market capitalisation of ₹1,03,572 Cr, against ₹90,916 Cr for Lupin (LUPIN). Over the past year Aurobindo Pharma has returned +61.9%, compared with +1.6% for Lupin. On valuation, Lupin trades at a lower P/E of 17.5 versus 26.0. Lupin earns a higher return on equity (21.6% vs 10.1%). Aurobindo Pharma comes out ahead on growth, financial health, momentum and technicals. Lupin comes out ahead on size, valuation and profitability. Across the scored metrics below, Aurobindo Pharma leads on 11 and Lupin on 7. On StoxGud's 10-point checklist, Aurobindo Pharma scores 9/10 and Lupin scores 7/10.
| Metric | Aurobindo Pharma | Lupin |
|---|---|---|
| Size | ||
| Market cap | ₹1,03,572 Cr | ₹90,916 Cr |
| Revenue (latest FY) | ₹33,653 Cr | ₹27,958 Cr |
| Net profit (latest FY) | ₹3,505 Cr | ₹5,333 Cr |
| Valuation | ||
| P/E | 26.0 | 17.5 |
| P/B | 2.63 | 3.78 |
| Dividend yield | 0.22% | 0.60% |
| Profitability | ||
| Return on equity | 10.1% | 21.6% |
| Net profit margin | 10.8% | 16.9% |
| Operating margin | 20.5% | 30.1% |
| Growth | ||
| Revenue growth (YoY) | +23.9% | +11.1% |
| Net profit growth (YoY) | +32.7% | -21.8% |
| Revenue CAGR (multi-year) | +6.3% | +13.0% |
| Financial health | ||
| Debt to equity | 0.21 | 0.23 |
| Momentum | ||
| 1-month return | +7.0% | -1.2% |
| 1-year return | +61.9% | +1.6% |
| 3-year CAGR | +27.2% | +18.3% |
| 5-year CAGR | +21.8% | +16.4% |
| 10-year CAGR | +8.9% | +2.7% |
| Distance from 52W high | +0.0% | -20.9% |
| Technicals | ||
| RSI (14) | 67 | 55 |
| Price vs 200-day avg | +22.4% | -11.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Aurobindo Pharma | Lupin |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 9/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Aurobindo Pharma or Lupin?
Aurobindo Pharma has a market cap of ₹1,03,572 Cr and Lupin has a market cap of ₹90,916 Cr as of 06 Nov 2026.
Which has a lower P/E, Aurobindo Pharma or Lupin?
Lupin has the lower P/E: Aurobindo Pharma trades at 26.0 and Lupin at 17.5.
Which gave better returns in the last year, Aurobindo Pharma or Lupin?
Aurobindo Pharma did better: Aurobindo Pharma returned +61.9% and Lupin returned +1.6% over one year.
Is Aurobindo Pharma or Lupin a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Aurobindo Pharma scores 9/10 and Lupin scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.